Olanzapine/fluoxetine (Symbyax) is an oral, once-daily, fixed-dose combination of the atypical antipsychotic olanzapine and the selective serotonin reuptake inhibitor (SSRI) fluoxetine. It is indicated, in adult patients, for the acute treatment of depressive episodes associated with bipolar I disorder and treatment-resistant major depressive disorder. In adult patients with treatment-resistant depression (major depressive disorder in adults who do not respond to two separate trials of different antidepressants of adequate dose and duration in the current episode), olanzapine plus fluoxetine combination therapy was generally more effective than either drug as monotherapy based on an integrated analysis of clinical trials of 8-12 weeks' duration. More limited data also indicate that longer-term treatment for 76 weeks with olanzapine plus fluoxetine was efficacious in this patient group. Combination therapy was generally well tolerated, with a tolerability profile similar to that of olanzapine monotherapy, although fluoxetine monotherapy was generally better tolerated than olanzapine plus fluoxetine. The combination of olanzapine plus fluoxetine, as a fixed-dose formulation, offers a useful treatment option in this difficult-to-treat patient group.

中文翻译：

---

奥氮平/氟西汀：对其在难治性重度抑郁症患者中的使用的综述。

奥氮平/氟西汀 (Symbyax) 是非典型抗精神病药奥氮平和选择性血清素再摄取抑制剂 (SSRI) 氟西汀的口服、每日一次、固定剂量组合。它适用于成人患者，用于与双相 I 型障碍和难治性重度抑郁症相关的抑郁发作的急性治疗。在患有难治性抑郁症的成年患者（在本次发作时对两种不同剂量和持续时间的不同抗抑郁药的独立试验没有反应的成人重度抑郁症）中，奥氮平加氟西汀联合治疗通常比任何一种药物作为单药治疗更有效基于对持续时间为 8-12 周的临床试验的综合分析。更有限的数据还表明，奥氮平加氟西汀的长期治疗 76 周在该患者组中是有效的。联合治疗通常耐受性良好，耐受性类似于奥氮平单药治疗，尽管氟西汀单药治疗通常比奥氮平加氟西汀耐受性更好。奥氮平加氟西汀的组合作为固定剂量制剂，为这一难以治疗的患者群体提供了一种有用的治疗选择。